Annual cashflow statement for VeraDermics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Net Income/Starting Line | -16.5 | -26.5 | -70 |
| Non-Cash Items | 2.06 | 2.07 | 2.93 |
| Other Non-Cash Items | |||
| Changes in Working Capital | 0.92 | 0.732 | -4.53 |
| Change in Prepaid Expenses | |||
| Change in Accounts Payable | |||
| Change in Accrued Expenses | |||
| Change in Other Liabilities | |||
| Cash from Operating Activities | -13.5 | -23.7 | -71.6 |
| Capital Expenditures | — | — | -0.024 |
| Purchase of Fixed Assets | |||
| Other Investing Cash Flow Items | — | — | -119 |
| Sale/Maturity of Investment | |||
| Purchase of Investments | |||
| Cash from Investing Activities | — | — | -119 |
| Financing Cash Flow Items | -0.035 | -0.283 | -0.447 |
| Other Financing Cash Flow | |||
| Net Issuance / Retirement of Stock | |||
| Net Issuance / Retirement of Debt | |||
| Cash from Financing Activities | 13.9 | 60.5 | 159 |
| Beginning Cash Balance | |||
| Ending Cash Balance | |||
| Net Change in Cash | 0.385 | 36.8 | -31.3 |